Specific antibodies of 95 health care workers vaccinated with inactivated 2019-nCoV vaccines

OBJECTIVE: To investigate the immune antibodies in blood specimens of 95 health care workers vaccinated with inactivated 2019-nCoV vaccines and explore the rules and characteristics of production of antibodies after vaccination. METHODS: From Oct 2020 to Jul 2021, the venous blood specimens were collected from 95 health care workers of the 305 Hospital of PLA after the injection of 2 doses of 2019-nCoV vaccines fo30 days, 65 days, 91 days, 6 months and 9 months. SARS-CoV-2 immunoglobin(Ig) M, IgG and titers of neutralizing antibodies and total antibodies were detected by chemiluminescence immunoassay, the results of antibody tests were dynamically analyzed, the immune durability of the antibody, influencing factors and correlation were determined. RESULTS: Almost all of the subjects produced IgG, neutralizing antibody and total antibody, some subjects retained high level of IgM titer. Smoking could affect the production of total antibody. The subjects of the low body weight group produced higher level of IgG, and there was no significant difference when the weight was over 60 kg. The titers of the four types of antibodies decreased significantly at the following time points, and the positive rates of all the antibodies were less than 50% except for IgG after the vaccination for 9 months. CONCLUSION: Specific IgM and IgG, neutralizing antibody and total antibody can be produced after the 2-doses vaccination of inactivated 2019-nCoV vaccines. But the titers and positive rates of the antibodies decrease with time, which means the protective effects on the body decrease. Therefore, in order to improve the autoimmunity against novel coronavirus, one booster vaccination of an inactivated 2019-nCoV vaccine will be necessary after the 2 doses of vaccination for 6 months.

Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying clinical manifestation severity of COVID-19

Background/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who re-covered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization). It is a challenge to find suitable donors. The aim of the study was to successively monitor antibody titer in donations and to investigate the correlation between an-tibody titer and the severity of the clinical manifestations. Methods. The retrospective study was conducted from May 1 to October 31, 2020, at the Blood Transfusion Insti-tute of Vojvodina. Donors had to meet certain criteria for inclusion in the study: proven SARS-CoV-2 infection, de-tected SARS-CoV-2 antibodies in the serum/plasma, ful-fillment of general criteria for performing plasmapheresis, and adequate laboratory findings. Results. During the study, 651 apheresis plasma units were collected and divided into two equal doses. Plasma was donated by 311 COVID-19 convalescents, including 208 (66.9%) men and 103 (33.1%) women. There were 15 (4.8%) plasma donors with asymptomatic infection, 235 (75. 6%) with a mild form of illness, 45 (14.5%) with a moderate form of illness, 16 (5.1%) with a severe form of illness, and none with a critical form of illness. Anti-SARS-CoV-2 IgG antibodies were pre-sent in the plasma of donors for more than 6 months after the disease. Plasma donors with a more severe clinical mani-festation of COVID-19 had stable antibody levels for a longer period. However, the Pearson correlation of clinical severity and antibody titer did not confirm a statistically sig-nificant correlation between the variables. Conclusion. An-ti-SARS-CoV-2 antibodies were present in the sample of re-covered patients, plasma donors, for more than 6 months after the disease. Even though no statistically significant correlation was found between the anti-SARS-CoV-2 anti-body titer and the clinical severity of COVID-19, in patients with a more severe clinical manifestations of the disease, stable antibody levels were maintained for a longer period.Copyright © 2022 Inst. Sci. inf., Univ. Defence in Belgrade. All rights reserved.

Analysis of serum SARS-CoV-2 antibody IgG tests after booster vaccination of COVID-19 vaccine in 205 individuals

Objective To analyze IgG test results of serum SARS-CoV-2 antibody in people after booster vaccinations against SARS-CoV-2, and to provide a basis for the booster vaccination. Methods There were 314 healthy individuals who had been vaccinated with the COVID-19 vaccine. Depending on their inoculation situation, they were divided into three groups:the booster injection group(1 week to 2 months after booster vaccination)of 205 cases, <180 days after two doses group(<180 days after two doses of COVID-19 vaccine)of 49 cases, and >180 days after two doses group(>180 days after two doses of COVID-19 vaccine)of 60 cases. The positive rate of IgG in serum of the three groups was measured using the colloidal gold method. Results The serum COVID-19 antibody IgG positive rates were 83.9% in the booster injection group, 18.4% in the <180 days after two doses group, and 5.0% in the >180 days after two doses group, with statistically significant difference between any two groups(all P < 0.05). In the booster injection group, the serum COVID-19 antibody IgG positive rate was 85.2% in people who received a booster injection more than a month, while those who received a booster injection less than a month had a positive rate of 75.9%, and there was no significant difference between these two groups(P > 0.05). In the booster injection group, the positive rates of serum COVID-19 antibody IgG were 85.1% in males and 82.4% in females, with no significant difference(P > 0.05). In the booster injection group, people at the age of 18 and 50 had a positive serum COVID-19 antibody IgG rate of 86.0%, while those over 50 had a positive rate of 58.3%, and there was significant difference between them(P < 0.05). Conclusions Compared with two injections of the COVID-19 vaccine, the booster injection can significantly increase the positive rate of the antibody IgG of COVID-19, which results in a stronger immune response. There is a lower IgG positive rate of COVID-19 antibodies in those aged over 50 years following the booster dose of COVID-19 vaccine than in those aged 18- 50 years.

Studying the efficacy, safety, and immunogenicity of the covishield vaccine in healthcare personnel in an Indian scenario

Background: COVID-19 has largely affected humans with high infection spread and mortality rates globally including India with no specific vaccine or therapy proven effective for its management as the immune response to COVID-19 is not well understood. Covishield has been largely distributed and administered in Indian subjects. However, its efficacy and safety are still unclear raising doubts. Aim: The present study aimed to assess the efficacy, safety, and immunogenicity of the Covishield vaccine in healthcare personnel in India. Methods: In 244 healthcare workers, SARS CoV2 IgG antibodies were assessed before and following the vaccination with two doses of Covishield given at 4 to 6 weeks apart. The efficacy of the vaccine and adverse effects after immunization were evaluated till two months after vaccination. The most common side-effect seen after the 1st dose was pain at the site of injection reported in 53.27% (n=130) study subjects followed by fever in 27.86% (n=68) study subjects, body ache in 22.95% (n=56) study subjects Results: Before vaccination, IgG was positive in 21.31% (n=52) study subjects and was negative in 78.68% (n=192) study subjects. Post-vaccination, IgG-positive status was seen in 69.67% (n=170) study subjects and was not seen in 30.32% (n=74) study subjects. In the infected group having 62 subjects, post-vaccination IgG positive was seen in 96.77% (n=60) study subjects and not seen in 3.22% (n=2) study subjects. In the uninfected group including the 182 subjects, post vaccination IgG positive was seen in 60.43% (n=110) study subjects and was not seen in 39.56% (n=72) study subjects respectively. After 2nd dose, the most common side-effect was pain at the site of injection seen in 24.59% (n=60) study subjects followed by headache in 12.29% (n=30) study subjects, fever in 7.37% (n=18) study subjects, body ache in 3.27% (n=8) participants, low backache and fatigue in 1.63% (n=4) study subjects each and local swelling in 0.81% (n=2) study subjects respectively. All the side effects had a non-significant difference except body ache which was significantly higher after 1st dose with p=0.02. Conclusion: Covishield vaccine has acceptable safety profile levels with increased seropositivity with more intervals in the two doses of the Covishield vaccine. Covishield does not prevent breakthrough infection. However, it can reduce the infection severity of COVID-19.

Exploring the potential therapeutic properties of bee products against COVID-19 (SARS CoV-2)

The new corona virus illness (COVID-19) swept around the world, quickly creating a serious international disaster. For the treatment and prevention of COVID-19, apitherapy appears to be a viable source of pharmacological and nutraceutical medicines. Honey, pollen, propolis, royal jelly, beeswax, and bee venom, for example, have been demonstrated to have significant antiviral action against infections that cause severe respiratory syndromes, including those produced by human corona viruses. Furthermore, many of these natural products are involved in the induction of antibody production, maturation of immune cells, and stimulation of innate and adaptive immunological responses and many of them are involved in the induction of antibody production, maturation of immune cells, and stimulation of innate and adaptive immunological responses.

Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease

Background: Data are limited regarding the safety of and antibody response to the BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid vaccine in adolescents and young adults with underlying disease. Methods: This prospective observational study enrolled patients age 12–25 years with chronic underlying disease who received 2 doses of BNT162b2. A 18-item questionnaire was used to assess adverse events within 7 days post-vaccination, and data regarding severe adverse events were collected from electronic medical records. An antibody titer for the receptor-binding domain of the spike protein in SARS-CoV-2 was used to assess antibody response after the second vaccine dose. Results: Study participants were 429 patients (241 [56.2%] age 12–15 years;188 [43.8%] age 16–25 years). The most common underlying diseases were genetic or chromosomal abnormalities and/or congenital anomalies, followed by endocrine or metabolic diseases;32% of participants were immunocompromised. Severe adverse events were observed after the second dose in 1 (0.4%) patient age 12–15 years and in 2 (1.1%) patients age 16–25 years;all patients recovered. Seropositivity after the second vaccine dose was 99.0%. The geometric mean antibody titer was higher in patients age 12–15 years versus 16–25 years (1603.3 [1321.8–1944.7] U/mL vs. 949.4 [744.2–1211.0] U/mL). Compared with immunocompetent patients, immunocompromised patients had a lower antibody titer (2106.8 [1917.5–2314.7] U/mL vs. 467.9 [324.4–674.8] U/mL). Conclusions: Vaccination with BNT162b2 was acceptably safe and immunogenic for adolescents and young adults with underlying disease. © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases

Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination

Vaccines having aided in escaping the majority of the population from immunological naïvety, our strategies are now shifting towards an increased focus on identifying and protecting the extremely vulnerable. We here describe the results of testing 12 patients, those with lymphoid malignancies having been targeted their B-cells for therapy with rituximab-containing regimens or a Bruton tyrosine kinase inhibitor, for anti-SARS-CoV-2 spike antibodies after receiving the BNT162b2 mRNA vaccine doses. The interval from last dosing of B-cell depletion therapy to SARS-CoV-2 vaccination was at median 5.3 (range 3.1–6.6) months. Using the ‘seroprotection' threshold of 775 [BAU/mL] for the anti-spike antibody titer, our finding points out the crucial unresponsiveness of the targeted population with 0/12 (0%) achieving ‘seroprotection'. Although IgG seroconversion was observed in 4/12 (33%), supporting the overall benefit of vaccination, the figures still point out a potential need for optimization of practice. IgA was further less responsive (unsuccessful ‘seroconversion' in 11/12 (92%)), implicating an underlying class switch defect. Those with depletion on B-cells are caught at a dilemma between, being too early and too late on receiving SARS-CoV-2 vaccines. They wish to get over their immunological naïvety at the earliest, while, in order to assure quality immune memory, are also required to hold the patience for their B-cells to repopulate. Although it remains an issue whether intensified vaccine schedules and/or regimens will lead to stronger immunogenicity or more effective boosters for non-responders, we shall take advantage of every increasing evidence in order to optimize current options. © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases

Lessons learned from global administration of sinopharm (BBIBP-CorV) vaccine and its efficacy against COVID-19 in older people

Sinopharm (BBIBP -CorV) is an inactivated whole -virus COVID -19 vaccine. The phase 3 trial showed an efficacy of up to 78% in preventing symptomatic COVID -19 infections. However, there have been questions raised regarding in its efficacy in older people. In this paper, several pertaining lessons are highlighted. Firstly, there is a need to take into account the heterogeneity of COVID -19 vaccine studies, such as representation of older people;and whether the results are generalizable to the target population of immunization programs. Secondly, for older people, antibody responses alone may not indicate the level of protection provided by the vaccines, as cell mediated immunity is a better determinant of immunity in this age group. Finally, suggestions are given to improve the immune responses in older people, such as heterologous vaccination and booster doses.

Transition in the SARS-CoV2 antibody profile after Pfizer/BioNtech vaccine inoculation in persons with and without a history of COVID-19

Objective: We investigated whether there was a difference in the antibody profile after Pfizer/BioNtech vaccination in persons who had already been infected with COVID-19 and those who had not. Method: Blood samples were obtained before, after the first dose and after the second dose of Pfizer/BioNtech vaccine inoculation in 4 subjects with a history of COVID-19 infection and 62 subjects without a history of COVID-19 infection after obtaining their informed consent. The differences in the antibody titers were examined between those with and without a prior history of COVID-19. Result: As compared with those without a prior history of COVID-19, those with a prior history of COVID-19 showed significantly higher antibody titers after the first inoculation, and the antibody titers were significantly higher than even those after the second inoculation of subjects without a prior history of COVID-19.

Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying clinical manifestation severity of COVID-19

Background/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who recovered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization). It is a challenge to find suitable donors. The aim of the study was to successively monitor antibody titer in donations and to investigate the correlation between antibody titer and the severity of the clinical manifestations. Methods. The retrospective study was conducted from May 1 to October 31, 2020, at the Blood Transfusion Institute of Vojvodina. Donors had to meet certain criteria for inclusion in the study: proven SARS-CoV-2 infection, detected SARS-CoV-2 antibodies in the serum/plasma, fulfillment of general criteria for performing plasmapheresis, and adequate laboratory findings. Results. During the study, 651 apheresis plasma units were collected and divided into two equal doses. Plasma was donated by 311 COVID-19 convalescents, including 208 (66.9%) men and 103 (33.1%) women. There were 15 (4.8%) plasma donors with asymptomatic infection, 235 (75. 6%) with a mild form of illness, 45 (14.5%) with a moderate form of illness, 16 (5.1%) with a severe form of illness, and none with a critical form of illness. Anti-SARS-CoV-2 IgG antibodies were present in the plasma of donors for more than 6 months after the disease. Plasma donors with a more severe clinical manifestation of COVID-19 had stable antibody levels for a longer period. However, the Pearson correlation of clinical severity and antibody titer did not confirm a statistically significant correlation between the variables. Conclusion. Anti-SARS-CoV-2 antibodies were present in the sample of recovered patients, plasma donors, for more than 6 months after the disease. Even though no statistically significant correlation was found between the anti-SARS-CoV-2 antibody titer and the clinical severity of COVID-19, in patients with a more severe clinical manifestations of the disease, stable antibody levels were maintained for a longer period. (English) [ FROM AUTHOR]

Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.

BACKGROUND AND AIMS: Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs. METHODS: In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response. RESULTS: Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response. CONCLUSION: Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines.

Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19.

BACKGROUND/AIMS: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers. METHODS: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose. RESULTS: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose. CONCLUSION: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.

A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: does trastuzumab interfere with the outcome?

Background: The COVID-19 pandemic has led to more than 260 million infections and 55 million deaths as of early December 2021, worldwide. Vaccinating people against COVID-19 is considered as he best approach to overcome the pandemic since COVID 19-vaccines are effective and can reduce the risk of getting and spreading the virus. However, their efficacy and safety in patients with underlying disease such as cancers have not been approved yet. Here we report a cohort study on immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer, who were vaccinated as a part of a national plan for vaccination of patients with special diseases.

Evaluation of vaccine "sputnik v" immunogenicity and reactogenicity when it is used in military personnel

The article presents the results of a study of the immunogenicity and reactogenicity of the vaccine Gam-COVID-Vac (Sputnik V) when used in military personnel undergoing military service on conscription. From 300 military personnel consistently vaccinated with one and two components of Gam-COVID-Vac at the intervals of 21 days, blood serum was obtained and examined three times: before vaccination, and 30 and 60 days after the introduction of the first component of the vaccine. In the blood serums, the content of Class G antibodies to the SARS-CoV-2 was determined by the method of solid-phase enzyme immunoassay. After immunization with the Gam-COVID-Vac vaccine, the average geometric titer of Class G antibodies to SARS-CoV-2 -in the blood serum of a military personnel obtained during the second and third examinations (5.02 log2 and 5.67 log2) increased by 2.4 and 2.7 times, respectively (p < 0.05), compared to the same indicator before the vaccination (2.11 log2). Total of 30 days after the introduction of the first component of the vaccine (Nine days after the introduction of the second component of the vaccine), Class G antibodies to the new coronavirus SARS-CoV-2 were detected in the 86.7% of military personnel, and after 60 days - in 92% of vaccinated. Studies have revealed moderate reactogenicity of the vaccine. Moreover, the proportion of postvaccination reactions in the first 3-5 days after the introduction of the second component of the vaccine was less after the introduction of the first component of the vaccine. So, if after the introduction of the first component of the vaccine, an increase in body temperature > 37 degrees C was observed in 20% of military personnel, then after the introduction of the second component only in 9%, and the share of local reactions decreased from 9-4%. There have been no cases of serious adverse events after immunization of military personnel with the Gam-COVID-Vac vaccine.

COVID-19 TANISI ALAN ÇOCUKLARIN B LENFOSÍT HÜCRELERÍNÍN VE ALT GRUPLARININ AKIŞ SÍTOMETRÍK DEĞERLENDÍRÍLMESÍ

Objective: During viral infections, antibody production of B cells are critical for protective immunity. It is known that the COVID-19 disease has a milder course in children. It is crucial to evaluate the causes of this situation from a pediatrician’s perspective to determine the treatment goals of the disease. We aimed to examine the flow cytometric changes in B cells and subtypes observed in children diagnosed with the COVID-19 infection. Materials and Methods: This is a prospective cohort study including 22 children aged 0-18 who had been diagnosed with COVID-19. CD19+B cells, CD27-IgD+ naive B, CD21low immature B, CD21lowCD- 38low active B, CD27-IgD- double-negative B, CD27- non-memory B, CD27+ memory B, CD27+IgD- switched memory B, and CD27+IgD+ non-switched memory B cells were studied using flow cytometry. Results: B cells counts decreased as a percentage in the 2-5 years age group and the 10-16 age group as an absolute number. Naive and non-memory B cell frequencies increased in the 5-10 years old and over 16 years old groups. Double negative B cells were normal in all age groups. Non-memory B cells increased in the 5-10 and over 16 years old groups, whereas memory B cells decreased. In all groups, switched memory B cells decreased. Non-switched memory B cell counts were within reference ranges in all groups except for the over 16 years group. Conclusion: Although the decrease in B cell count is associated with the severity of the disease, naive B cell subgroups did not decrease in the pediatric patients included in the study. All groups showed increased switched memory B cell counts, in accordance with the literature. Unlike adults, naive B cells, non-switched memory B cells, and double-negative B cells were normal in children. (English) [ FROM AUTHOR] Amaç: Viral enfeksiyonlar sırasında B hücrelerinin antikor üretimi, koruyucu bağışıklık için kritiktir. Çocuklarda COVID-19 hastalığının daha hafif seyrettiği bilinmektedir. Bu durumun nedenlerini çocuk doktoru gözüyle değerlendirmek, hastalığın tedavi hedeflerini belirlemek açısından çok önemlidir. COVID-19 enfeksiyonu tanısı alan çocuklarda gözlenen B hücre ve alt tiplerinde akım sitometrik değişiklikleri incelemeyi amaçladık. Gereç ve Yöntem: Çalışmamız 0-18 yaş arası COVID-19 teşhisi konulan 22 çocuğu içeren prospektif kohort bir araştırmadır. CD19+B hücreleri, CD27-IgD+ saf B, CD21düşük olgunlaşmamış B, CD21düşükCD38düşük aktif B, CD27-IgD- çift negatif B, CD27- bellek B, CD27+ bellek B, CD27+IgD- dönüşmüş (switched) bellek B, CD27+IgD+ dönüşmemiş (non-switched) bellek B hücreleri akış sitometrisi ile incelenmiştir. Bulgular: B hücre sayısı 2-5 yaş grubunda yüzde olarak, 10-16 yaş grubunda ise mutlak sayı olarak azaldı. 5-10 yaş ve 16 yaş üstü gruplarda naif ve hafıza dışı B hücrelerinin oranları arttı. Çift negatif B hücreleri tüm yaş gruplarında normaldi. Bellek dışı B hücreleri 5-10 yaş arasında ve 16 yaş üzerinde artarken, aynı gruplarda bellek B hücreleri azaldı. Dönüşmüş bellek B hücreleri tüm yaş gruplarında azaldı. Dönüşmemiş bellek B hücreleri, 16 yaşın üzerinde azaldı ve diğer tüm yaş gruplarında normal görünüyordu. Sonuç: B hücre sayısındaki azalma hastalığın şiddeti ile ilişkili olmasına rağmen, çalışmaya dâhil edilen çocuk hastalarımızda naif B hücre alt gruplarında azalma olmadı. Literatüre uygun olarak tüm gruplarda dönüşmüş bellek B hücreleri arttı. Çocuklarda yetişkinlerden farklı olarak naif B hücreleri, dönüşmemiş bellek B hücreleri ve çift negatif B hücreleri normaldi. (Turkish) [ FROM AUTHOR] Copyright of Istanbul Tip Fakültesi Dergisi is the property of Istanbul Tip Fakultesi Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Dynamic changes in production of antibodies against SARS-CoV-2 based on three serological kits

We wished to understand the dynamic changes in production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in sera collected from coronavirus disease 19 (COVID-19) patients. Fifty-eight serum samples from 33 patients confirmed to have COVID-19 in Gansu Province, China, were tested for three types of SARS-CoV-2-specific antibodies: immunoglobulin (Ig) M, IgG, and total antibodies. The positive rate of IgM, IgG and total antibodies increased gradually with COVID-19 progression. Within the first 3 days, the positive rate of detection of SARS-CoV-2-specific antibody using the three kits was 13.6%-31.8%. whereas, within 4-7 days, it was 36.4%-45.5%, within 8-14 days it was 55.6%-77.8%, and after 15 days, it was 100%. In addition, the three kits were used to measure antibodies from serum samples collected from healthy people, and the specificity was 99%-100%. Statistical analyses indicated no significant difference among the results of the three kits (P > 0.05 for all). In summary, the three SARS-CoV-2 antibody-detection kits had good sensitivity and specificity for detection of antibodies against SARS-CoV-2, and could aid the clinical diagnosis of COVID-19. The dynamic characteristics of production of SARS-CoV-2- specific antibodies could provide important scientific bases for epidemiologic investigations.

Special issue on new coronavirus (2019-nCoV or SARS-CoV-2) and the outbreak of the respiratory illness (COVID-19): part-XX. (Special issue on new coronavirus (2019-nCoV or SARS-CoV-2) and the outbreak of the respiratory illness (COVID-19): part-XX.)

This special issue contains 74 articles (2 commentaries, 17 letters to the editor, 8 reviews, 40 research articles, 7 short communications) that discusses topics related to COVID-19 and its variants. Topics include new drugs against COVID-19, detection of variants, antibody response, evolution and phylogeny, monoclonal antibodies, symptoms, among others.

Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac.

The ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines. Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) S protein IgG antibodies and thrombodynamics parameters in individuals vaccinated with Gam-COVID-Vac and CoviVac vaccines. Material and methods. The study included 137 people who completed the first 3 visits: 30 people received the Gam-COVID-Vac, 107 people -- CoviVac. The study participants underwent venous blood sampling before the introduction of the 1st and 2nd vaccine doses, as well as 42 days after the administration of 1st dose in order to quantify the level of IgG antibodies. At each visit, plasma hemostasis parameters were analyzed using a thrombodynamics test. Results. During the follow-up period, there was a clear increase in the level of anti-SARS-CoV-2 S protein IgG antibodies in both groups. At the same time, this increase over time was significantly greater in Gam-COVID-Vac group. There was no correlation detected between thrombodynamics test results and the levels of anti-SARS-CoV-2 S protein IgG antibodies. Conclusion. The data obtained demonstrate the ability of both vaccines to stimulate the production of anti-SARS-CoV-2 antibodies. However, immune response to Gam-COVID-Vac is much higher. The lack of correlation between thrombodynamics and the level of specific antibodies suggests that vaccination for COVID-19 with Gam-COVIDVac and CoviVac does not cause changes in plasma hemostasis and does not increase the risk of thrombosis. (English) [ FROM AUTHOR] Продолжающаяся пандемия новой коронавирусной инфекции (COVID-19, COronaVIrus Disease 2019) делает крайне актуальным изучение иммуногенности, длительности сохранения иммунного ответа и безопасности имеющихся вакцин. Цель. В рамках проспективного наблюдательного исследования изучить ассоциации между уровнем IgG к S белку коронавиру- са SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2) и параметрами тромбодинамики у лиц, вакцинированных против SARS-CoV-2 вакцинами Гам-КОВИД-Вак и КовиВак. Материал и методы. В исследование включено 137 человек, кото- рые полностью прошли первые 3 визита: 30 человек получили вак- цину Гам-КОВИД-Вак, 107 человек -- КовиВак. У участников иссле- дования проводился забор венозной крови перед введением I-го и II-го компонентов вакцины, а также через 42 дня со дня введения I-го компонента с целью количественного определения уровня IgG к S белку. На каждом из визитов проводился анализ показателей плазменного гемостаза при помощи теста тромбодинамики. Результаты. В течение периода наблюдения отмечалась отчетли- вая динамика нарастания уровня IgG антител (АТ) к S белку в обеих группах. При этом увеличение уровня АТ в динамике было значи- тельно бóльшим в группе лиц, вакцинированных Гам-КОВИД-Вак. По результатам исследования плазменного звена гемостаза кор- реляционной связи между уровнями IgG АТ на каждом визите и па- раметрами тромбодинамики выявлено не было. Заключение. Полученные данные демонстрируют способность обеих вакцин стимулировать выработку АТ к SARS-CoV-2. Однако выраженность иммунного ответа на введение Гам-КОВИД-Вак значительно выше. Отсутствие корреляции между показателями тромбодинамики и уровня специфических АТ говорит о том, что вакцинация против COVID-19 вакцинами Гам-КОВИД-Вак и КовиВак не вызывает изменений плазменного гемостаза и не увеличивает риск тромбообразования. (Russian) [ FROM AUTHOR] Copyright of Cardiovascular Therapy & Prevention is the property of Silicea-Poligraf LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.

BACKGROUND: Patients with cancer were excluded from phase 3 COVID-19 vaccine trials, and the immunogenicity and side effect profiles of these vaccines in this population is not well understood. Patients with cancer can be immunocompromised from chemotherapy, corticosteroids, or the cancer itself, which may affect cellular and/or humoral responses to vaccination. PD-1 is expressed on T effector cells, T follicular helper cells and B cells, leading us to hypothesize that anti-PD-1 immunotherapies may augment antibody or T cell generation after vaccination. METHODS: Antibodies to the SARS-CoV-2 receptor binding domain (RBD) and spike protein were assessed in patients with cancer (n=118) and healthy donors (HD, n=22) after 1, 2 or 3 mRNA vaccine doses. CD4+ and CD8+ T cell reactivity to wild-type (WT) or B.1.617.2 (delta) spike peptides was measured by intracellular cytokine staining. RESULTS: Oncology patients without prior COVID-19 infections receiving immunotherapy (n=36), chemotherapy (n=15), chemoimmunotherapy (n=6), endocrine or targeted therapies (n=6) and those not on active treatment (n=26) had similar RBD and Spike IgG antibody titers to HDs after two vaccinations. Contrary to our hypothesis, PD-1 blockade did not augment antibody titers or T cell responses. Patients receiving B-cell directed therapies (n=14) including anti-CD20 antibodies and multiple myeloma therapies had decreased antibody titers, and 9/14 of these patients were seronegative for RBD antibodies. No differences were observed in WT spike-reactive CD4+ and CD8+ T cell generation between treatment groups. 11/13 evaluable patients seronegative for RBD had a detectable WT spike-reactive CD4+ T cell response. T cells cross-reactive against the B.1.617.2 variant spike peptides were detected in 31/59 participants. Two patients with prior immune checkpoint inhibitor-related adrenal insufficiency had symptomatic hypoadrenalism after vaccination. CONCLUSIONS: COVID-19 vaccinations are safe and immunogenic in patients with solid tumors, who developed similar antibody and T cell responses compared with HDs. Patients on B-cell directed therapies may fail to generate RBD antibodies after vaccination and should be considered for prophylactic antibody treatments. Many seronegative patients do develop a T cell response, which may have an anti-viral effect. Patients with pre-existing adrenal insufficiency may need to take stress dose steroids during vaccination to avoid adrenal crisis.

Results of the questionnaire on the presence of viral infection (COVID-19) of A.N. Syzganov NSCS employees

According to the WHO, there are 60.3 million officially registered COVID-19 casesin the world, 38.6 million recovered, and a death rate of 1.42 millionby November 25, 2020. Kazakhstan is also one of the countries severely affected by COVID-19. In the period from the end of June to July 2020, there was a sharp increase in the incidence in Kazakhstan, moreover, Kazakhstan was in the "red" zone due to the disappointing epidemiological situation. A study of the viral infection (COVID-19) epidemiological situationamong employees of the A.N. Syzganov NSCS. The centerstaff were studied by the method of polymerase chain reaction (PCR) diagnostics, enzyme-linked immunosorbent assay (ELISA) testing (for antibodies to SARS-CoV-2), chemiluminescent immunoassay (CLIA) (to identify common antibodies to SARS-CoV-2) and computer tomography (CT) of the chest. In total, the study included 384 employees of the NSCS aged from 21 to 80 years, average age was 44.1 +or- 0.3.81 men and 303 women were examined: 54 of them were doctors, 188 nurses, 90 junior medical staff, and the other 52 employees. In total, 384 employees were interviewed (questioned), 174 (45.7%) were infected with a viral infection according to the questionnaire. In accordance with studyresults, it can be concluded that 76.6% of NSCS employees have had a viral infection (COVID-19) and a sufficient immune layer has formed in the team to maintain a favorable epidemiological situation in the next six months. Based on the studyresults, we recommend, that it is inappropriate to determine antibodies to COVID-19 within a month, it is better to determine using the CLIA method after three months.